RxDoctor Payments Data

Nidal Jboor, MD

Internal Medicine · Dearborn Heights, MINPI 1679543425

Payments from drug & device makers

$357in general payments, 2019–2025

Across 15 payments — averaging $23.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$139
  • Boehringer Ingelheim$99
  • Novartis$18
  • Alkermes, Inc.$18
  • Galderma Laboratories, L.p.$16
  • Exact Sciences$15
  • plus $52 from 4 others

What the payments were for

  • Food & beverage$357100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$357 in reported general payments places this provider in the 60th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$66,676
Medicare patients
62
Services billed
952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide110$138,023
JardianceEmpagliflozin100$90,149
JanuviaSitagliptin Phosphate62$45,043
EliquisApixaban46$37,628
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$37,093
JanumetSitagliptin Phos/Metformin Hcl34$32,009
LinzessLinaclotide39$28,128
OzempicSemaglutide20$19,099
Oxymorphone Hcl ErOxymorphone Hcl13$11,541
FarxigaDapagliflozin Propanediol17$11,153
Janumet XrSitagliptin Phos/Metformin Hcl16$8,796
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$5,439
Breo ElliptaFluticasone/Vilanterol11$4,245
Novolog FlexpenInsulin Aspart16$4,142
Diclofenac Sodium48$2,500

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$13$138,023110 claims
Boehringer IngelheimJardiance$99$90,149100 claims
GSKTrelegy Ellipta, Breo Ellipta$139$41,33857 claims
PfizerEliquis$13$37,62846 claims
AbbVieLinzess$13$28,12839 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Dearborn Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →